NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer
MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Sam Jackson, MD, MBA, as Chief Medical Officer. Dr. Jackson will work alongside the Chief Executive Officer and Board of Directors to shape and execute the Company’s clinical development strategy.